Sustained Virologic Response (SVR) to Direct-Acting Antiviral (DAA) Therapy in Patients with Chronic Hepatitis C Virus (HCV) Infection and Hepatocellular Carcinoma (HCC): a Systematic Review and Meta-Analysis
Fanpu Ji,Mike Wei,Yee Hui Yeo,Bin Wei,Eiichi Ogawa,Dong Hyun Lee,Masaru Enomoto,Hidenori Toyoda,Michelle B. Bass,John Lubel,Tatsuya Ide,Carmen Monica Preda,Etsuko Iio,Fabio Conti,Tatsuya Minami,Rob Bielen,Hitomi Sezaki,Michele Barone,Po-Sung Chu,Victor Virlogeux,Dennis Eurich,Takanori Kanai,Shuangsuo Dang,Zongfang Li,Norihiro Furusyo,Fabien Zoulim,Pietro Andreone,Ramsey Cheung,Yasuhito Tanaka,Akihiro Tamori,Mindie H. Nguyen
DOI: https://doi.org/10.1016/s0168-8278(18)30733-5
IF: 25.7
2018-01-01
Journal of Hepatology
Abstract:Background: Chronic HCV infection is known to negatively affect quality of life and other patient-reported outcomes (PROs), while its clearance often results in sustained PRO improvement, especially in patients with cirrhosis.Aim: To assess changes in PROs in cirrhotic patients initially randomized to placebo treatment who subsequently received ledipasvir/ sofosbuvir (LDV/SOF) + ribavirin (RBV) in a phase 2 clinical trial (the SIRIUS study: compensated cirrhotics with HCV genotype 1, France, 2013France, -2014)).Methods: HCV-infected patients with cirrhosis who received 12 weeks of placebo treatment subsequently received LDV/SOF+RBV daily for 12 weeks.The PROs were prospectively collected during placebo and active treatment using SF-36v2, CLDQ-HCV, FACIT-F, and WPAI:SHP.Results: Of 76 patients in the initial placebo arm of SIRIUS, 75% were male, 99% white, and 21% had history of depression; the SVR-12 rate was 96%.During treatment with placebo, there was no significant changes in any of the PROs from patients' own baseline levels (all p>0.05) except for the Worry domain of CLDQ-HCV.After initiation of treatment with LDV/SOF+RBV, a significant improvement in Emotional domain of CLDQ-HCV was also noted, while all other PROs remained at their baseline levels (all p>0.05).However, cessation of treatment and achieving SVR were associated with significant improvement of PRO scores: +4.5% to +7.2% of a PRO range size from the baseline level, p<0.05 for 4 out of 26 studied PROs, by posttreatment week 4; +4.1% to +11.6%, p<0.05 for 17/26 PROs, by SVR-12; +6.1% to +16.7%, p<0.05 for 24/26 PROs, by SVR-24.The greatest improvements were observed in the domains of Vitality, Fatigue, Worry, and Activity (>13% of a PRO range size by SVR-24).In multivariate analysis, adjusted for clinico-demographic confounders and the impact of receiving RBVcontaining treatment, being viremic was associated with a significant impairment in PRO scores: betas from -2.5% to -7.8%, p<0.05 for 17/26 PROs.Conclusions: Cirrhotic patients with HCV treated with placebo show no improvement of their PRO scores.In contrast, PRO scores substantially improved after SVR-12 in the same group of patients treated with DAA regimens.